FIGUR8 reported a new round of financing and expanded product offerings targeting the low back, neck, lumbar spine and knee to take the guesswork out of musculoskeletal health evaluations.

According to a media release, the company has raised $12 million in Series A financing led by Taiwania Capital with participation from new and existing investors that include the MIT-affiliated E14 Fund, Phoenix Venture Partners, and P5 Health Ventures, among others.

"The strong demand we've seen from clinicians have underscored the critical need for quantitative evaluation of musculoskeletal disorders," said Nan-Wei Gong, CEO and cofounder of FIGUR8. "We've developed the most powerful wearable musculoskeletal diagnostic technology on the market to bring precision analytics to musculoskeletal health. Today's expanded product offerings and new financing will power FIGUR8's deployment with major health systems, government organizations and large employers."

FIGUR8's system enables a full musculoskeletal and orthopedic assessment to be conducted in minutes by anyone, anywhere, regardless of technical or clinical expertise, and serves as a more effective solution than MRIs and X-rays for screening soft tissue-related symptoms.

"FIGUR8's advanced technology is a tremendous breakthrough in the care of patients with musculoskeletal injuries," said Dr. Julio Jose Caballero Salgado, medical director at MAPFRE. "We have always had tools like EKG for fast cardiovascular assessments, and now, thanks to FIGUR8, we have a new powerful tool to assess the level of soft tissue injuries and recovery."

More information:

www.figur8tech.com

((Comments on this story may be sent to newsdesk@closeupmedia.com))